Andere Sprachen ENDRA Life Sciences Inc.

Aktien

A3DZZU

US29273B3024

NDRA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 20.05.2024			% 5 Tage	% 1. Jan.
0,32 ^USD	+4,20 %		+9,93 %	-84,91 %

14.05.	Transcript : ENDRA Life Sciences Inc., Q1 2024 Earnings Call, May 14, 2024
10.05.	ENDRA Life Sciences Inc. gibt Gewinnprognose für das am 31. März 2024 endende Quartal ab	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ENDRA Provides Update Following In-person Meeting with FDA	20.05.
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update	14.05.
Endra Life Sciences Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024	14.05.
ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024	10.05.
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024	07.05.
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents	02.05.
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	28.03.
ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024	21.03.
ENDRA Life Sciences Installs First TAEUS System in the UK	27.02.
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences TAEUS System	22.02.
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System	21.02.
ENDRA Life Sciences Inc. Welcomes the Adoption of the ICD-10 K76.0 Code for the Diagnosis of Non-Alcoholic Fatty Liver Disease	21.02.
ENDRA Life Sciences Bolsters TAEUS System Intellectual Property with New Patents in U.S., China and Europe	15.02.
ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe	14.02.
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS System Technology	30.11.
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology	29.11.
ENDRA Life Sciences to participate in the Benchmark Company's 12th Annual Discovery One-on-One Investor Conference	28.11.
ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference	27.11.
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ENDRA Life Sciences Inc.

Aktien

A3DZZU

US29273B3024

NDRA

Andere Sprachen

Filter